Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Paola Antonini, MD, PhD
Senior Vice President
Scientific Affairs
Worldwide Clinical Trials
King of Prussia, PA
Senior Vice President, Scientific Affairs, Worldwide Clinical Trials, King of Prussia, PA
Authored Items
Demonstrating Value for Biosimilars: A Conceptual Framework
Sally Amanuel, MSc, MA, MBA
,
Michael Kleinrock
,
Paola Antonini, MD, PhD
,
Victoria Coutinho, MSc, PhD
,
Thomas Goss, PharmD
,
Zhihong Lai, PhD
,
Sotiris Rompas, Phd
,
Michael F. Murphy, MD, PhD
May 2015, Vol 8, No 3
in
Business
Postapproval Development Options in COPD: A Case Study in Value-Based Healthcare Systems
Paola Antonini, MD, PhD
,
Zhihong Lai, PhD
,
Michael F. Murphy, MD, PhD
January/February 2011, Vol 4, No 1
in
Regulatory
Last modified: June 3, 2015